Found 5 matching trials
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). PHASE1 This is a Phase Ib, open label, dose escalation study of spartalizumab + LA...
Show More Location
Columbia University Medical Center- New York Presbyterian Columbia
Learn More & Join Trial
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies PHASE2 The purpose of this signal seeking study is to determine whether treatment ...
Show More Location
California Pacific Medical Center Drug Shipment (2)
Learn More & Join Trial
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma PHASE2 The primary purpose of this study is to evaluate the efficacy of novel spar...
Show More Location
The Angeles Clinic and Research Institute
Learn More & Join Trial
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. PHASE1 This study was to characterize the safety, tolerability, pharmacokinetics (...
Show More Location
Columbia University Medical Center SC LAG X2101C
Learn More & Join Trial
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer PHASE2 The main purpose of this study was to assess the antitumor activity of thre...
Show More Location
Ironwood Cancer and Research Centers
Learn More & Join Trial